Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8}) Clinical Trial Registry" to "$1 $1") |
||
| Line 46: | Line 46: | ||
</div> | </div> | ||
===References=== | ===References=== | ||
| − | # '''SWOG S9005:''' Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. [https://doi.org/10.1200/JCO.2015.61.6490 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26527781/ PubMed] [https://clinicaltrials.gov/study/NCT03015701 | + | # '''SWOG S9005:''' Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. [https://doi.org/10.1200/JCO.2015.61.6490 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669593/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26527781/ PubMed] [https://clinicaltrials.gov/study/NCT03015701 NCT03015701] |
[[Category:Meningioma regimens]] | [[Category:Meningioma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] | ||
Revision as of 11:46, 4 July 2023
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
- NCCN does not have guidelines at this granular level; please go to the Central Nervous System Cancers category page.
Unresectable, all lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | 1992-1998 | Phase 3 (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701